Mitazalimab, in combination with standard chemotherapy, has exhibited continued promising efficacy and safety in treating ...

Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising ...

The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...

Survival and Progression Metrics: Secondary and exploratory endpoints include duration of response, sustained MRD negativity, biochemical and clinical progression-free survival (PFS), time to a ...

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.